Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845476 | 1.00 | ALDH1A1 (0.45) | ALDH1A1NPSR1CA2MEN1KMT2A | |
| SCHEMBL30486880 | 1.00 | ALDH1A1 (0.45) | ALDH1A1NPSR1CA2MEN1KMT2A | |
| SCHEMBL4860312 | 1.00 | ALDH1A1 (0.45) | ALDH1A1NPSR1CA2MEN1KMT2A | |
| SCHEMBL10305099 | 0.87 | GAA (0.47) | ALDH1A1NPSR1CA2MEN1KMT2A | |
| SCHEMBL4860844 | 0.87 | GAA (0.47) | ALDH1A1NPSR1CA2MEN1KMT2A | |
| SCHEMBL10305084 | 0.87 | GAA (0.47) | ALDH1A1NPSR1CA2MEN1KMT2A | |
| SCHEMBL12767468 | 0.86 | RECQL (0.46) | ALDH1A1NPSR1MEN1KMT2AHPGD | |
| SCHEMBL12767504 | 0.86 | RECQL (0.46) | ALDH1A1NPSR1MEN1KMT2AHPGD | |
| SCHEMBL9183556 | 0.85 | GAA (0.45) | ALDH1A1MEN1KMT2AHPGDPOLB | |
| SCHEMBL7002095 | 0.79 | GAA (0.51) | ALDH1A1MEN1KMT2AHPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006134469-A1 | METHODS OF PREPARING MEK INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-12-21 | — | — | WO | claimed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3624796-B1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0242482-B1 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1995-09-06 | — | — | EP | disclosed |
| US-4965270-A | Viricides | BEECHAM GROUP P.L.C. (GB) | 1990-10-23 | — | — | US | disclosed |
| EP-0242482-A2 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | AADAC, EGLN3, HCAR2 | ALDH1A1 363/4885NPSR1 1424/4885CA2 338/4885 |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, PRKDC, MAPK1 | ALDH1A1 450/4885NPSR1 3155/4885CA2 2525/4885 |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | ALDH1A1 527/4885NPSR1 3444/4885CA2 3995/4885 |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | ALDH1A1 527/4885NPSR1 3444/4885CA2 3995/4885 |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | ALDH1A1 527/4885NPSR1 3444/4885CA2 3995/4885 |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | VHL, NRAS, KRAS | ALDH1A1 774/4885NPSR1 874/4885CA2 1340/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | ALDH1A1 200/4885NPSR1 2165/4885CA2 772/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | ALDH1A1 436/4885NPSR1 1343/4885CA2 288/4885 |
| US-20240216307-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | QDPR, DHFR, NEFM | ALDH1A1 701/4885NPSR1 453/4885CA2 2711/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | ALDH1A1 479/4885NPSR1 1741/4885CA2 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.